Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces an abstract describing a drug-drug interaction study assessing the effect of CYP2C9 inhibitor, fluconazole, on the pharmacokinetics of nebulized ensifentrine in healthy individuals has been published by the European Respiratory Society International Congress 2021.
September 2, 2021
· 7 min read